After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Pharmaceutical companies just raised list prices for over 500 medicines, including Novo Nordisk’s Ozempic, Gilead’s HIV-1 ...

Shareholders request Human Rights Due Diligence to determine whether pharma companies do everything they can to increase drug ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively ...